Article

A data-driven Alzheimer’s disease progression simulator for retrospective validation and prospective Phase III power design

2026-05-05

Abstract excerpt

Anti-amyloid immunotherapies have recently demonstrated the first significant slowing of cognitive decline in Alzheimer’s disease (AD), yet clinical benefit varies markedly across drugs and scales with the completeness of amyloid clearance. Pharmacokinetic/pharmacodynamic (PK/PD) models are currently the standard tool for trial simulation, but they typically operate on single biomarkers and rely on drug-concentrat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d1dd8520-891e-54e3-a91f-2f327ef37c85
DOI: 10.64898/2026.05.03.26352317

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A data-driven Alzheimer’s disease progression simulator for retrospective validation and prospective Phase III power designDOI 10.64898/2026.05.03.26352317Read

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read

Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 TreatmentSemantic proximity Read

Mapping U.S. POINTER Cognitive-Slope Gains Onto Predicted Clinical Progression: An External-Cohort Translation Analysis With Exploratory Economic ThresholdsSemantic proximity Read

Computational Risk Stratification of Preclinical Alzheimer’s in Younger AdultsSemantic proximity Read

Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer’s DiseaseSemantic proximity Read

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach.Semantic proximity Read

Multi-method investigation of factors influencing amyloid onset and impairment in three cohortsSemantic proximity Read

An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.Semantic proximity Read

Learning a Continuous Progression Trajectory of Amyloid in Alzheimer diseaseSemantic proximity Read

An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Semantic proximity Read

Functional-vs-Cognitive Decline Heterogeneity in Alzheimer’s Disease: LLM-Curation of Decades of Clinical Notes and GLP1RA Trial DesignSemantic proximity Read

Simulating the outcome of amyloid treatments in Alzheimer’s disease from imaging and clinical dataSemantic proximity Read